Member Info for Timster

Bonkers init like science day data never happened. Exactly as truant wants you to believe, no new data was released.

But look, it's still there and it's still very very good:
https://avacta.com/therapeutics-science-day-recording-and-presentations/

Thanks richar I topped up today too

Good news, when's the 20p placing?

As I said earlier I don't think the wider market (other than those they wanted to see it) would have even had a look as the RNS stated it wasn't new information.
And it would have the. Involved effort checking the avacta website to see when it was available as they didn't announce it other than saying it'd be there 24hrs after the event.

Been discussed to death but there was tons of new data like all the data from the trial and all the preclinical 3996 data.

Great post JT and yes wow for ava6k!

100k worth of "unknown" trades, size buyer?

What did you think of it tiger, the 3996 data looked very good I thought and the Ava6k emerging data was superb. The redesign of phase 1b a master stroke dyou think?
What did you think of the oncology experts from America? Not impressed that they want anything to do with Avacta?
Keen to here your views...

Although the science day rns stated the presentation and video would be available after the event it also said there was no new information.
There clearly was a raft of expanded useful information so have they gone and shot themselves in the foot there as only excitable pi's and those invited to the day would have read it.
The rest of the financial world think there is nothing in it

Dr William Tap is a very good man to have on board.

Cohort 5 details, must be soon.

Bird flu LFT (joke)

Still a very low chance of success? Even knowing what they know!

Absolutely, the scientific board and chief investigators are top drawer. He's built a hell of a team.

How dare you call me a moron....

After hours prints Hurstbot?

Also an RNS confirmation of the two US sites which have already been confirmed in science day slides.

Lots of news to come, there was actually no mention of cohort 5 starting or started during the day so that should be soon

Does make you wonder why they changed P1b design to have a control arm with pure dox. Hmmm

If you can't be ****d to look at the science day slide deck or just watch the ava6k trial progress part of the presentations then have a look at the data sheet.
https://avacta.com/wp-content/uploads/2023/02/preCISION-technology-datasheet-2023.pdf

And if you can't even be ****d with that these are the key advantages:
Tumour targeting - localised release of therapeutic agents in the tumour, including chemotherapies, small molecules and other agents
FAPa-activated form of chemotherapies - limiting systemic exposure Potential to significantly increase safety and therapeutic potential of cancer treatments

I'll help you out gje then you don't need to moan again
https://www.fca.org.uk/markets/market-abuse/how-report-suspected-market-abuse-individual

Have you sent a strongly worded email to the FCA yet?

DTwig you replied to the wynbore thread, but your post deserves its own thread, hope you don't mind:
Some absolute garbage on here this morning, sadly, distracting from the fantastic content of last week's SD.

It's difficult to ignore, I agree but unless you are planning to sell your shares imminently it is almost irrelevant if the SP sits at £1.45 or £2.45. There are only three important questions that SH's should be asking themselves this morning:

1. Does it work? we now know the unequivocal answer to this question. Unfortunately most of the posters this morning are too thick and lazy to have read/listened to anything from the SD.
2. Does the science have commercial value? - Myles M and RAH have gone to great length to provide rationale to this question, I have yet to read a single sentence from any aquatic mammal that can provide a sensible contradiction to their assessments.
3. Do Avacta have the cash to progress to commercialisation? - Regardless of your perspective, this is the one question that cannot be answered.
What we do know however: (all in RNS's)
A) - AVCT received 'a minimum' of £45 million in November from the convertible bond offering of which they needed £24 million to buy Launch
B) They also received an extra £7 million in October from the 95p raise
C) They were sat on £17 million cash at end June 2022
D) They lost £9 million first 6 months of 2022

If we assume that the losses are all cash (which may not be the case) and you don't count any 'new' revenues from Launch this would infer that they are burning £1.5 million per month against a cash pile of circa £40 million, or just over 2 years of cash runway.
Can they progress the pipeline to commercialisation within this time frame? That is the only question that matters and after reading and listening to the contents of the SD (I have), there is no doubt in my mind that this will happen well in advance of any shortage of working cap
Ignore the noise, ignore the SP, read the RNS,s and SD material